PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief E

Dr. Davis brings more than 20 years of industry experience to lead the advancement of the company’s clinical stage pipeline of T-SIGn® immuno-oncology therapeutics for the treatment of solid tumorsNew CEO will establish U.S. operations in the Boston area to accelerate the company’s mission to positively impact the l...

Related Keywords

Boston , Massachusetts , United States , Duncan Higgons , Priya Mande , Mike Beyer , Howard Davis , Yale University , Psioxus Therapeutics Ltd , Healthcare Communications , Novartis , Sam Brown Inc , Atlas Venture , Boston Consulting Group , Parker Institute For Cancer Immunotherapy , Psioxus Therapeutics , Chief Executive , Chief Operating Officer , Third Harmonic Bio , Flagship Pioneering , Chemical Engineering , Harvard University , Massachusetts Institute , Technology Division , Health Sciences , Specific Immuno Gene , Parker Institute ,